L-NAME Hydrochloride: Benchmark NOS Inhibitor for Vascular Research

Executive Summary: L-NAME Hydrochloride, also known as NG-nitro-L-arginine methyl ester, is a potent, competitive NOS inhibitor with an IC₅₀ of approximately 70 μM, validated in brain and endothelial models (product information). The compound robustly suppresses nitric oxide production, allowing precise modulation of vascular tone and inflammation (related article). In vivo, L-NAME Hydrochloride reliably induces hypertension and bradycardia in rats—effects reversible by L-arginine administration. Its water solubility (≥27 mg/mL) and stability at -20°C support broad applicability across cellular and animal models. APExBIO supplies rigorously quality-controlled L-NAME Hydrochloride (SKU: A7088), supporting reproducible cardiovascular disease model research.

Biological Rationale

Nitric oxide (NO) is a critical signaling molecule involved in neurotransmission, vascular tone regulation, gene transcription, mRNA translation, and post-translational protein modifications. The synthesis of NO is catalyzed by nitric oxide synthase (NOS) isoforms, including endothelial (eNOS), neuronal (nNOS), and inducible (iNOS). Dysregulation of NO production is implicated in hypertension, inflammation, and endothelial dysfunction (International Immunopharmacology, 2026). Targeted inhibition of NOS has become foundational to vascular tone regulation studies and the modeling of cardiovascular disease pathophysiology. L-NAME Hydrochloride enables researchers to dissect NO-dependent mechanisms in both normal and disease states, offering a precise approach for apoptosis and inflammation signaling modulation.

Mechanism of Action of L-NAME Hydrochloride

L-NAME Hydrochloride acts as a competitive inhibitor of nitric oxide synthase. Structurally analogous to L-arginine, it binds to the active site of NOS enzymes, blocking access of the natural substrate. This results in dose-dependent suppression of NO synthesis. In rat brain and porcine aorta preparations, L-NAME Hydrochloride inhibits NOS activity with an IC₅₀ around 70 μM (product page). The blockade of NO production leads to increased vascular tone, elevated systemic arterial pressure, and altered inflammatory signaling. In vitro, 1 mM L-NAME Hydrochloride reduces NO and prostaglandin E2 levels, and downregulates iNOS and COX-2 expression in retinal cell models under hyperglycemic conditions. In vivo, intravenous administration (0.03–300 mg/kg) produces dose-dependent hypertension and bradycardia, reversible with L-arginine supplementation, confirming selectivity for the NOS pathway.

Evidence & Benchmarks

• L-NAME Hydrochloride inhibits NOS in rat brain and porcine aorta tissue with an IC₅₀ of ~70 μM (product information).
• In vivo, intravenous L-NAME induces sustained, dose-dependent increases in systemic arterial blood pressure and bradycardia in rats, effects reversed by L-arginine (product information).
• At 1 mM in cell culture, L-NAME Hydrochloride decreases NO and prostaglandin E2 production, suppressing iNOS and COX-2 expression and reducing apoptosis in high-glucose-exposed retinal cells (product information).
• Animal models employ intravenous L-NAME at 0.03–300 mg/kg to modulate vascular responses, supporting its use in hypertension and cardiovascular disease model workflows (protocol review).
• The FXR-KLF11-JAK2/STAT3 axis is a validated pathway for apoptosis and inflammation modulation in renal injury models, highlighting the translational relevance of NOS pathway manipulation (International Immunopharmacology, 2026).

This article extends insights from "L-NAME Hydrochloride: Optimizing NOS Inhibition for Vascular Research" by detailing molecular benchmarks and clarifying in vivo protocol variations, and from "Precision NOS Inhibition in Hypertension Models" by integrating apoptosis and inflammation endpoints within cardiovascular models.

Applications, Limits & Misconceptions

L-NAME Hydrochloride is a cornerstone NOS inhibitor for vascular tone regulation, hypertension research, and inflammation pathway delineation. It is widely used to model endothelial dysfunction and interrogate NO-mediated signaling in cardiovascular disease models, both in vitro and in vivo. The compound's solubility in water and DMSO, but not ethanol, enables a range of experimental setups. However, its effects are context-dependent and reversible by L-arginine, underscoring its specificity.

Common Pitfalls or Misconceptions

• L-NAME Hydrochloride is not an irreversible NOS inhibitor; its actions are reversible with L-arginine supplementation (product page).
• It does not selectively inhibit a single NOS isoform; all three (nNOS, eNOS, iNOS) are targeted to varying degrees.
• High doses may produce off-target effects, including systemic toxicity, if not titrated carefully.
• The compound is not stable in solution long-term and should be freshly prepared for each use (product page).
• Results may not predict human pharmacodynamics due to species-specific vascular responses.

Workflow Integration & Parameters

Successful use of L-NAME Hydrochloride in research requires careful attention to solubility, dosing, and experimental design. APExBIO provides detailed guidance to ensure reproducibility across labs.

Protocol Parameters

• Stock solution preparation: Dissolve in water (≥27 mg/mL) or DMSO (≥23 mg/mL); avoid ethanol as solvent (product page).
• Storage: Store powder at -20°C. Prepare fresh solutions for each experiment; avoid repeated freeze-thaw cycles.
• In vitro dosing: Use 1 mM to inhibit NO and prostaglandin E2 production in cell models; titrate based on cell type and endpoint (product page).
• In vivo dosing: Typical intravenous range is 0.03–300 mg/kg for rat models; titrate to achieve desired vascular effect. Monitor for hypertension and bradycardia as efficacy readouts.
• Reversal: Co-administration of L-arginine can restore NO synthesis, confirming pathway specificity (product page).

Conclusion & Outlook

L-NAME Hydrochloride from APExBIO is a validated, potent NOS inhibitor essential for vascular tone regulation studies, apoptosis and inflammation signaling modulation, and the development of hypertension and cardiovascular disease models. Its well-characterized action profile, solubility, and reversibility enable robust, reproducible workflows for dissecting NO-dependent pathways. The compound's role is further underscored by recent mechanistic insights into the interplay between NO, inflammation, and apoptosis in acute organ injury (International Immunopharmacology, 2026). While L-NAME Hydrochloride is indispensable for preclinical cardiovascular research, careful protocol design remains essential to avoid confounding artifacts. Future studies will refine its applications as new endpoints and translational strategies emerge.